Abstract
We performed a multivariate gene-by-environment genome-wide interaction study (GEWIS) of suicidality in 123,633 individuals using a covariance matrix based on 26 environments related to traumatic experiences, posttraumatic stress, social support, and socioeconomic status. We discovered sex-specific risk loci exhibiting interaction effects driven by PTSD, including the male-specific rs2367967 (CWC22), which replicated in an independent cohort. Sex-specific cell-type transcriptome enrichment, gene-based analyses, and locus annotation point to extracellular matrix biology and synaptic plasticity as biological mediators of the effects of lifetime traumatic experiences on genetic risk for suicidality.
Competing Interest Statement
Dr. Kranzler is a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which for the past three years was supported by AbbVie, Alkermes, Amygdala Neurosciences, Arbor, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, and Pfizer. Dr. Kranzler is paid for his editorial work on the journal Alcoholism: Clinical and Experimental Research. Drs. Kranzler and Gelernter are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. Dr. Murray Stein is paid for his editorial work on the journals Biological Psychiatry and Depression and Anxiety, and the health professional reference Up-To-Date. Drs. Polimanti and Gelernter are paid for their editorial work on the journal Complex Psychiatry. The other authors declare no competing interests.
Funding Statement
This study was supported by the National Center for PTSD of the U.S. Department of Veterans Affairs, the American Foundation for Suicide Prevention (YIG-1-109-16), the National Institutes of Health (F32 MH122058, R21 DC018098, R21 DA047527, R01 DA12690), and the U.S. Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment and the VISN 4 Mental Illness Research, Education and Clinical Center. The content is solely the responsibility of the authors and do not necessarily represent the views of the funding agencies. This research has been conducted using the UK Biobank Resource (application reference no. 58146).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Summary level data used in the project are made available for download on the UKB data access portal (https://biobank.ctsu.ox.ac.uk/crystal/browse.cgi?id=-2&cd=search) or from their referenced publications. Individual level data are available from UKB to bona fide researchers through the UKB Access Management System.
https://biobank.ctsu.ox.ac.uk/crystal/browse.cgi?id=-2&cd=searc